Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Retained Earnings: 2022-2024

Historic Retained Earnings for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to -$397.0 million.

  • Corvus Pharmaceuticals' Retained Earnings fell 3.92% to -$400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.0 million, marking a year-over-year decrease of 3.92%. This contributed to the annual value of -$397.0 million for FY2024, which is 18.61% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Retained Earnings of -$397.0 million as of FY2024, which was down 18.61% from -$334.7 million recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Retained Earnings high stood at -$307.7 million for FY2022, and its period low was -$397.0 million during FY2024.
  • In the last 3 years, Corvus Pharmaceuticals' Retained Earnings had a median value of -$334.7 million in 2023 and averaged -$346.5 million.
  • Data for Corvus Pharmaceuticals' Retained Earnings shows a maximum YoY decreased of 18.61% (in 2024) over the last 5 years.
  • Corvus Pharmaceuticals' Retained Earnings (Yearly) stood at -$307.7 million in 2022, then dropped by 8.78% to -$334.7 million in 2023, then dropped by 18.61% to -$397.0 million in 2024.